Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Cincinnati, Ohio 45229


The purpose of this research study is to see if giving Omegaven (an intravenous fat emulsion containing fish oil) instead of the current lipid emulsion, which contains fat derived from soybeans, as part of your child's intravenous (IV) nutrition therapy may be tolerated better. It may reduce the harmful effects to the liver, may stop any further liver damage and may reverse damage already done to the liver because of the prolonged use of nutrition through your child's IV.

Study summary:

Enrollment of subjects into this study will occur for up to 4 years. Subjects will receive Omegaven at a dose of up to 1 g/kg body weight/day until they no longer require total parenteral nutrition or until their conjugated/direct bilirubin has normalized and their enteral lipid intake is sufficient to discontinue intravenous lipids.


Inclusion Criteria: - Males and females ages one month of age to 18 years of age - Patients with intestinal failure on TPN - Patients who have a conjugated/direct bilirubin of ≥3 mg/dl for more than weeks and in whom other causes of cholestasis have been excluded with reasonable certainty utilizing biochemical, serologic, microbiologic, and radiographic techniques. Liver biopsy is not required to rule out other disorders, but may be utilized at the clinician's discretion - Patients in whom reduction of IV soy-based lipid to an average <1.2g/kg body weight/day has failed to reduce the conjugated/direct bilirubin within ≥ 30 days of implementation - Willing to use birth control during study participation for females of child- bearing potential, as determined by investigator. - Signed informed consent for use of Omegaven® obtained Exclusion Criteria: - Any of the contraindications to use of Omegaven® - Impaired lipid metabolism (triglycerides >1000 mg/dL) while on 1g/kg/day or less of Intralipid - History of severe hemorrhagic disorders (ie. hemophilia, Von Willebrand disease, etc.) - Unstable diabetes mellitus - Collapse and shock - Stroke/ Embolism - Cardiac infarction within the last 3 months - Undefined coma status - Pregnancy (positive pregnancy test) prior to enrollment in the study for females of child-bearing potential - Females of child-bearing potential who are unwilling to use birth control during study participation - Parental decision to forego the use of Omegaven® - Known fish or egg allergy - Pregnancy - Causes of liver disease other than PNAC



Primary Contact:

Principal Investigator
Samuel Kocoshis, MD
Children's Hospital Medical Center, Cincinnati

Backup Contact:


Location Contact:

Cincinnati, Ohio 45229
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.